uniQure (NASDAQ:QURE) Issues Quarterly Earnings Results

uniQure (NASDAQ:QURE) posted its quarterly earnings data on Tuesday. The biotechnology company reported ($0.85) EPS for the quarter, beating the consensus estimate of ($0.88) by $0.03, FiscalAI reports. The firm had revenue of $3.56 million during the quarter, compared to analyst estimates of $5.21 million. uniQure had a negative net margin of 1,154.42% and a negative return on equity of 145.81%.

Here are the key takeaways from uniQure’s conference call:

• uniQure has a scheduled Type B meeting with the FDA later this quarter to discuss the statistical analysis plan for the 4‑year AMT‑130 data and design elements of a new study, and plans a MAA submission in the U.K. in Q3 based on 3‑year data, creating near‑term regulatory catalysts.
• Enrollment in the Phase I/II‑A study of AMT‑260 for refractory mesial temporal lobe epilepsy is on track, with safety, tolerability and seizure‑frequency results from the first 6‑patient cohort (≥6 months) expected in Q2 and the company targeting a meaningful seizure‑reduction signal to guide dose selection.
• AMT‑191 (Fabry) showed dose‑dependent, durable increases in alpha‑gal A and all 11 dosed patients have discontinued enzyme replacement therapy, but dosing at mid/high cohorts was paused after two asymptomatic grade‑3 liver enzyme elevations and the program is continuing follow‑up while dosing at the low dose.
• The company has discontinued development of AMT‑162 for SOD1‑ALS after a serious adverse event of dorsal root ganglia toxicity in one patient, and will continue safety follow‑up for the five dosed patients.
• uniQure ended Q1 with $586.6 million in cash, equivalents and investments and states this is sufficient to fund operations into H2 2029, though management noted future prioritization will be required to preserve the runway.

uniQure Stock Performance

Shares of QURE stock traded up $1.33 during trading hours on Thursday, hitting $24.15. 1,934,534 shares of the company were exchanged, compared to its average volume of 2,836,348. The firm has a fifty day simple moving average of $16.67 and a 200 day simple moving average of $24.97. The company has a current ratio of 10.40, a quick ratio of 10.43 and a debt-to-equity ratio of 0.33. uniQure has a 52-week low of $8.73 and a 52-week high of $71.50. The stock has a market capitalization of $1.52 billion, a price-to-earnings ratio of -6.94 and a beta of 0.87.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on QURE shares. TD Cowen reiterated a “buy” rating on shares of uniQure in a research note on Tuesday, March 3rd. Royal Bank Of Canada upgraded shares of uniQure from a “sector perform” rating to an “outperform” rating and raised their price target for the stock from $11.00 to $35.00 in a research note on Monday, March 9th. Chardan Capital raised their price target on shares of uniQure from $31.00 to $37.00 and gave the stock a “buy” rating in a research note on Thursday, April 30th. Sanford C. Bernstein lowered shares of uniQure to a “market perform” rating in a research note on Tuesday, March 3rd. Finally, Wolfe Research assumed coverage on shares of uniQure in a research note on Monday, February 23rd. They set a “peer perform” rating for the company. Ten research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, uniQure presently has an average rating of “Moderate Buy” and a consensus target price of $42.83.

Insider Buying and Selling

In related news, CEO Matthew C. Kapusta sold 14,581 shares of the firm’s stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $9.06, for a total value of $132,103.86. Following the completion of the transaction, the chief executive officer directly owned 660,658 shares of the company’s stock, valued at approximately $5,985,561.48. This trade represents a 2.16% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Jeannette Potts sold 3,412 shares of the firm’s stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $9.06, for a total transaction of $30,912.72. Following the completion of the transaction, the insider directly owned 138,483 shares of the company’s stock, valued at approximately $1,254,655.98. This trade represents a 2.40% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 49,396 shares of company stock valued at $722,734. Company insiders own 4.79% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. CIBC Private Wealth Group LLC bought a new position in uniQure in the 3rd quarter worth approximately $50,000. Smartleaf Asset Management LLC bought a new position in uniQure in the 4th quarter worth approximately $48,000. Ensign Peak Advisors Inc boosted its holdings in uniQure by 21.7% in the 4th quarter. Ensign Peak Advisors Inc now owns 3,650 shares of the biotechnology company’s stock worth $87,000 after buying an additional 650 shares during the period. Knott David M Jr boosted its holdings in uniQure by 100.0% in the 4th quarter. Knott David M Jr now owns 4,000 shares of the biotechnology company’s stock worth $96,000 after buying an additional 2,000 shares during the period. Finally, Deutsche Bank AG boosted its holdings in uniQure by 98.3% in the 4th quarter. Deutsche Bank AG now owns 4,621 shares of the biotechnology company’s stock worth $111,000 after buying an additional 2,291 shares during the period. 78.83% of the stock is owned by institutional investors.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.